Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025SAN FRANCISCO, (GLOBE NEWSWIRE) -- FibroGen, Inc.
Targeted Oncology

Imetelstat as a Treatment Option for Low-risk MDS

Discover how a metal statin offers a promising backup treatment for MDS patients, enhancing transfusion outcomes while ...
Targeted Oncology

Imetelstat as a Second-line Therapy Option in Low-risk MDS

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...
The American Journal of Managed Care

Examining Treatment Algorithms for MDS

Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...
Cure Today

MDS Treatment Advances: Targeted Therapies and Anemia Management

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Healio

VIDEO: Recent MDS treatment, diagnostic developments

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. We all know that MDS is a cancer of the ...
Healio

Five-day azacitidine best among shorter hypomethylating agent regimens for low-risk MDS

A decade-long investigation of shorter regimens of hypomethylating agents for low-risk myelodysplastic syndrome revealed a ...

Chromatin accessibility maps reveal how stem cells drive myelodysplastic syndrome progression

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and ...
Cure Today

Early Transfusions, Treatments May Improve Outcomes in Low-Risk MDS

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS. Receiving early red blood cell transfusion for low-risk ...
The American Journal of Managed Care

Clinicians, Caregivers, Patients: MDS Treatment Preferences Explored

Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...
Business Wire

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of ...
Healthline

Ask the Advocate: How Do You Fight for the Best MDS Treatment on Behalf of Your Loved One?

Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...